1. In Table1, the authors showed the demographics and clinicopathological characteristics of NSCLC patients stratified with histopathological subtype. However, in the manuscript, they explained the total number of patients and it is confusing. They should show the data about clinicopathological data of total NSCLC patients in Tabel1 and also clinicopathological characteristics stratified with CD133 SNPs. 2. In discussion, The authors indicated that for NSCLC patients with rs2240688A>C variant genotypes, the therapeutic effect may be enhanced by controlling the expression of CD133. However, they do not show any data about the relationship between CD133 SNPs and CD133 expression in this study. They should correct the discussion part.
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GENERAL COMMENTS
In "Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome of non-small cell lung cancer in Chinese population" Qing-Feng and colleagues present the results of a candidate gene association study in 1,383 Chinese patients with non-small cell lung cancer (NSCLC) . They analyze four single nucleotide polymorphism in CD133 and report an association of one marker with overall survival. This is a candidate gene association study in a moderately sized sample from one center. While written relatively clearly with a plausible candidate gene, the paper suffers from several methological weaknesses. In general I refer to the existing special guidance beyond STROBE for genetic association studies (i.e. STREGA) which should be followed. Below I listed several major and specific remarks below that the authors might find useful:
• I wonder if and why or why not the listed SNPs (or marker alleles in linkage disequilibrium) are not reported in the genome-wide association study (GWAS) catalog (for NSCLC and overall survival)? And why are no references provided for the existing GWAS in the introduction?
• it seems that the same data (citation 19) was used recently in a case-control study -please comment Table 3 , I also see that there are differences in the Stage I/II versus III disease groups, and in the Wedge Resection group; these should be mentioned; perhaps they are proxies for the same signal, but this should be discussed later. c. STROBE checklist: Some items are absent, when they could be listed: e.g. #10: Convenience sample; #11: time to even was used in days (?); #12(b) stratification was used by subgroup factors; and #17: subgroup analyses were done and reported in Table 3 . d. I advise the authors to use the STREGA statement checklist, rather than STROBE. It has many of the same items, but more applicable to a genetic study. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634792/ 3) Discussion should be added to: a. The Hazard Ratios are largely very similar in all subgroups, and similar to the overll (unadjusted) HR; this (subjectively) implies no confounding by the factors looked at
Minor comments: -Abstract: Correct misspelling of "Hazard ratio" as "Hazard ration" -Discussion: CD133 should be referred to in the singular -gene not genes, locus not loci -Discussion 3'UTRs should be singular - Table 2 . For rs2240688 the results "Dominant" and "Recessive" are swapped - Table 3 . Title should point out the genetic model assumed (dominant for the C allele)
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Jun Sakakibara-Konishi Hokkaido University School of Medicine, Japan Please state any competing interests or state "None declared": None delcared
Please leave your comments for the authors below In this study, the authors investigated the SNPs in CD133 and the correlation of prognosis in NSCLC in a Chinese population. However, there are several questions about their results.
1. In Table1, the authors showed the demographics and clinicopathological characteristics of NSCLC patients stratified with histopathological subtype. However, in the manuscript, they explained the total number of patients and it is confusing. They should show the data about clinicopathological data of total NSCLC patients in Tabel1 and also clinicopathological characteristics stratified with CD133 SNPs.
Thanks for reviewer"s insightful suggestions. Clinicopathological data of total NSCLC patients is shown in Table 1 according to reviewer"s suggestions However,. Table 1 will be too large if clinicopathological characteristics are shown stratified with CD133 SNPs. Table 1 was mainly used to show demographic and clinicopathological characteristics of NSCLC patients, instead of showing the relationship between clinicopathological characteristics and CD133 SNPs. And the purpose of the study is to determine the effects of CD133 SNPs on survival of lung cancer patients.
2. In discussion, The authors indicated that for NSCLC patients with rs2240688A>C variant genotypes, the therapeutic effect may be enhanced by controlling the expression of CD133. However, they do not show any data about the relationship between CD133 SNPs and CD133 expression in this study. They should correct the discussion part.
We agree with reviewer"s suggestions on this topic. The inference and conclusion have been deleted from the revised manuscript.
Reviewer: 2 Anne-Marie Baird St. James's Hospital, Ireland Please state any competing interests or state "None declared": I have no competing interests. Thanks for reviewer"s constructive advice. The manuscript title has been revised as suggested.
The miRNA which targets the SNP is described -what is the miRNA which targets the wildtype CD133?
The miRNA which targets the wildtype CD133 include miR-34a, -101, -128, -137 and -138. And the miRNA which targets the SNP is described in our revised manuscript.
Can the authors comment on why CD133 was chosen over other cancer stem cell markers?
The CD133 antigen, also known as prominin-1, has been used extensively as a biomarker of CSCs among different types of tumors, including colon cancer, liver cancer, gastric cancer, brain tumor, endometrial cancer and ovarian cancer. A recent case-control study conducted by our team in a Chinese population showed that the rs2240688 variant AC/CC genotypes were associated with a statistically increased risk of lung cancer. Therefore, we hypothesized the associations between four functional SNPs in CD133 and the prognosis of non-small cell lung cancer in a Chinese population. Above information has been included into the introduction section.
Reviewer: 3 André Scherag Jena University Hospital, Germany Please state any competing interests or state "None declared": None declared -
--------------------------------------------------Please leave your comments for the authors below
In "Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome of nonsmall cell lung cancer in Chinese population" Qing-Feng and colleagues present the results of a candidate gene association study in 1,383 Chinese patients with non-small cell lung cancer (NSCLC). They analyze four single nucleotide polymorphism in CD133 and report an association of one marker with overall survival. This is a candidate gene association study in a moderately sized sample from one center. While written relatively clearly with a plausible candidate gene, the paper suffers from several methological weaknesses. In general I refer to the existing special guidance beyond STROBE for genetic association studies (i.e. STREGA) which should be followed. Below I listed several major and specific remarks below that the authors might find useful:
STREGA checklist has been included instead of STROBE checklist as supplementary files. All necessary information has been supplemented according to STREGA checklist.
Thanks reviewer for his constructive suggestions. However, the listed SNPs were not selected from the genome-wide association study (GWAS) catalog (for NSCLC and overall survival). Candidate CD133 gene SNPs with potentially functional significance were selected based on NCBI dbSNPs (http://www.ncbi.nlm.nih.gov) and SNPinfo Web Server (http://www.snpinfo.niehs.nih.gov/snpfunc.htm). The listed SNPs have been investigated in a casecontrol study to explore the relationship between CD133 gene SNPs and risk of lung cancer. Therefore, the same SNPs among these patients are used to determine the associations between four functional SNPs in CD133 and the prognosis of NSCLC in a Chinese population.
• it seems that the same data (citation 19) was used recently in a case-control study -please comment
As reviewer specified, part of the same data in the case-control study was used as the baseline data of the current cohort study. And we have clarified in the methods section as following: "All participants with NSCLC in a case-control study which identified the relationship between polymorphisms of CD133 and the risk of lung cancer were included in the retrospective cohort study."
• the authors perform multiple statistical tests and apply no multiple testing corrections Sub-group analysis and different specific genetic models were used to analyze the relationship between polymorphisms of CD133 and overall analysis of lung cancer patients. It is not compulsory to conduct multiple testing corrections in sub-groups, and we do sub-group analysis when the overall association is significant. It is also accepted to explore the association of SNPs with disease under specific models without corrections. The association of SNPs with diseases has been explored under different genetic models by a great many studies without multiple testing corrections. However, we have considered the potential impact as a study limitation as following: "our study had made many comparisons in statistical analyses, which might increase type I error."
• some of the applied tests may not be robust for small absolute cell counts (exact methods will be required) -e.g in case of recessive models
The analysis with small absolute cell counts was done with exact methods in our study, and we have clarified this in our statistical analysis methods.
• power considerations are completely missing
Sample size estimation was added in the revised manuscript according to reviewer"s suggestions.
• what about population stratification issues in China?
Almost all the study participants were Han ethnicity, confounding by ethnic origin is not a major problem in the current study. And population stratification is based on demographic and clinicopathological characteristic of participants.
• as the most important requirement a replication attempt is missing (see also my GWAS comment) to better rule out false positive findings (e.g. resulting from multiple testing or genotyping errors for rs2240688)
Thanks reviewer for his suggestions on this topic. We have considered the problem before submission. However, the detailed laboratory testing methods has been published in the case-control study. So we just clarified in the methods section: "The genotyping methods of the four CD133 SNPs are described in detail elsewhere". The detailed methodology has been shown in this reference as following: "Genomic DNA was isolated from blood sample with a DNA blood Mini Kit (Qiagen Inc., Valencia, California, USA) according to the manufacturer"s instructions. The genotyping was carried out using the TaqMan methodology (Applied Biosystem platform, Carlsbad, California, USA) and the outputs were read with a TaqMan 7900HT sequence detection system according to the manufacturer"s instructions. The reactions were prepared using TaqMan Universal Master Mix, 80 9 SNP Genotyping Assay Mix, Dnase-free water, and 10 ng genomic DNA in a final volume of 5 ul per reaction. Each plate included both negative and positive controls and repeated samples to ensure the accuracy of the genotyping. The polymerase chain reaction (PCR) amplification was run and the conditions were as follows: 50 ?C for 2 min, 95 ?C for 10 min followed by 40 cycles of 95 ?C for 15 s, and 60 ?C for 1 min. The final fluorescence results were automatically calculated into the genotypes using the built-in software of the system."
• finally any practical, clinical implications should be omitted as this is basic research which needs more validation and other studies with other study designs to qualify as biomarker for clinical applications
We agreed that this is a basic research, the speculation on clinical implications has been deleted from the revised manuscript. For example, " for NSCLC patients with rs2240688A>C variant genotypes, the therapeutic effect may be enhanced by controlling the expression of CD133" has been deleted from discussion and conclusion section. - 
This work is of high quality despite its simplicity, and seems a valuable and solid addition to the literature. I find the design and the analysis to be correct and valid so far as reported. Some minor additions or clarifications are recommended:
1) The methods section should give some more detail: a. Clarify what is meant by "immediate blood relatives" -are these first degree only? (parents, sblings and children)
Thanks for reviewer"s careful checking. It has been revised according to suggestions.
b. Some more detail on why these four SNPs were selected would be important -their position or function in the gene; what was the linkage disequilibrium pattern between them?
The position of these four SNPs in the gene has been described in the revised manuscript. And the function rs2240688 of has been shown in the discussion section.
c. The statistical methods (Cox regression) should clarify that the data were analysed under specific genetic models; I can deduce you looked at it 4 ways: genotypic (categorical), additive (linear allelic), and also assumming a recessive or a dominant mode.
This has been clarified in the statistical analysis methods section.
d. The extent to which this cohort of patients overlaps the one the authors have reported on previously (reference 19) should be made clear.
